BTG PLC Directorate Change (3807W)
November 14 2017 - 2:01AM
UK Regulatory
TIDMBTG
RNS Number : 3807W
BTG PLC
14 November 2017
BTG plc: Directorate change - Chief Financial Officer
London, UK, 14 November 2017: BTG plc (LSE: BTG), the global
specialist healthcare company, announces that after 10 years as
Chief Financial Officer (CFO) at BTG, Rolf Soderstrom is to step
down as an Executive Director of the Company. The Board intends to
appoint Duncan Kennedy to succeed Rolf as CFO on 1 January 2018.
Rolf will remain with the Company until completion of a smooth
handover to Duncan, which is expected to be concluded by 31 March
2018.
Duncan currently leads BTG's Interventional Oncology business, a
role he has held since May 2015. He joined BTG in December 2005 as
Group Financial Controller and became a member of the Leadership
Team in April 2012 when he was appointed Group Director of Finance,
with responsibility for managing the global finance function and
supporting the CFO. Prior to joining BTG, Duncan spent six years in
the group finance function of Wembley plc. Duncan qualified as a
Chartered Accountant at Arthur Andersen and holds a BSc in
Mathematics from Durham University.
"The Board is grateful to Rolf for his many significant
contributions to BTG since joining the Company in 2008 following
the acquisition of Protherics, and we wish him well for the
future," said Garry Watts, BTG's Chairman. "We are also delighted
to appoint Duncan as CFO, and look forward to continuing working
with him in his new role as we further expand BTG's business."
Louise Makin, BTG's CEO, commented: "I would like to add my
personal thanks to Rolf for all his support over the past 10 years,
while we have worked together to build the company. I also look
forward to working with Duncan as our new CFO as we continue to
take BTG forwards."
There are no further disclosures to be made under rule 9.6.13 of
the Listing Rules.
For further information contact:
BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABXLLFDFFLFBQ
(END) Dow Jones Newswires
November 14, 2017 02:01 ET (07:01 GMT)
Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024
Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024